Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab

INTRODUCTION: At the clinical introduction of antiangiogenic agents as anticancer agents, no major toxicities were expected as merely just endothelial cells (ECs) in tumors would be affected. However, several (serious) toxicities became apparent, of which underlying mechanisms are largely unknown. W...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Angiogenesis
Autors principals: Walraven, Maudy, Homs, Marjolein Y. V., van der Veldt, Astrid A. M., Dekker, Henk, Koldenhof, Jose, Honeywell, Richard, Barendrecht, Arjan, Sebastian, Silvie A. E., Parr, Naomi, Koekman, Arnold C., Voest, Emile E., Roest, Mark, Korporaal, Suzanne J. A., Verheul, Henk M. W.
Format: Artigo
Idioma:Inglês
Publicat: Springer Netherlands 2018
Matèries:
Original Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5878190/
https://ncbi.nlm.nih.gov/pubmed/29532289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10456-018-9598-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars